Ilia I. Ouspenski

Array ( [id] => 8989260 [patent_doc_number] => 20130216541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'STABLE SUBCUTANEOUS PROTEIN FORMULATIONS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/796586 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 25579 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13796586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9427642 [patent_doc_number] => 08703718 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-22 [patent_title] => 'Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule' [patent_app_type] => utility [patent_app_number] => 13/795545 [patent_app_country] => US [patent_app_date] => 2013-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 102 [patent_figures_cnt] => 125 [patent_no_of_words] => 48976 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13795545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10541833 [patent_doc_number] => 09266945 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-23 [patent_title] => 'Human anti-B7RP1 neutralizing antibodies' [patent_app_type] => utility [patent_app_number] => 13/794265 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 25878 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13794265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9469003 [patent_doc_number] => 08722632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-05-13 [patent_title] => 'Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule' [patent_app_type] => utility [patent_app_number] => 13/788970 [patent_app_country] => US [patent_app_date] => 2013-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 102 [patent_figures_cnt] => 125 [patent_no_of_words] => 48951 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13788970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081046 [patent_doc_number] => 20130266577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'USE OF A CD28 BINDING SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION' [patent_app_type] => utility [patent_app_number] => 13/783959 [patent_app_country] => US [patent_app_date] => 2013-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 7463 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13783959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10233265 [patent_doc_number] => 20150118260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-30 [patent_title] => 'Recombinant Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4)' [patent_app_type] => utility [patent_app_number] => 14/389013 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 16561 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14389013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915413 [patent_doc_number] => 09783591 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Use of the CD2 signaling domain in second-generation chimeric antigen receptors' [patent_app_type] => utility [patent_app_number] => 14/375999 [patent_app_country] => US [patent_app_date] => 2013-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24949 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14375999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9951346 [patent_doc_number] => 09000133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-07 [patent_title] => 'Antibodies to OX-2/CD200 and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/771911 [patent_app_country] => US [patent_app_date] => 2013-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 73 [patent_figures_cnt] => 75 [patent_no_of_words] => 31973 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13771911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10069528 [patent_doc_number] => 09107862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-18 [patent_title] => 'Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics' [patent_app_type] => utility [patent_app_number] => 13/767891 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 128 [patent_figures_cnt] => 141 [patent_no_of_words] => 125951 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13767891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8853130 [patent_doc_number] => 20130142805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-06 [patent_title] => 'COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 13/766900 [patent_app_country] => US [patent_app_date] => 2013-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 20128 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13766900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989228 [patent_doc_number] => 20130216509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'CHIMERIC RECEPTORS WITH 4-1BB STIMULATORY SIGNALING DOMAIN' [patent_app_type] => utility [patent_app_number] => 13/761917 [patent_app_country] => US [patent_app_date] => 2013-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 21132 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13761917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916782 [patent_doc_number] => 20150071987 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'IMMUNOSTIMULATORY COMPOSITIONS, PARTICLES, AND USES RELATED THERETO' [patent_app_type] => utility [patent_app_number] => 14/374729 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11955 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14374729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8820969 [patent_doc_number] => 20130122014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 13/746773 [patent_app_country] => US [patent_app_date] => 2013-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44040 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13746773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9882766 [patent_doc_number] => 08969531 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-03-03 [patent_title] => 'Anti-CD80 antibody' [patent_app_type] => utility [patent_app_number] => 13/739300 [patent_app_country] => US [patent_app_date] => 2013-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 8319 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13739300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9112886 [patent_doc_number] => 08569054 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-29 [patent_title] => 'Mammalian cell lines for increasing longevity and protein yield from a cell culture' [patent_app_type] => utility [patent_app_number] => 13/735244 [patent_app_country] => US [patent_app_date] => 2013-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 29 [patent_no_of_words] => 18542 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13735244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9850405 [patent_doc_number] => 08952136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-10 [patent_title] => 'Antibodies to human programmed death receptor PD-1' [patent_app_type] => utility [patent_app_number] => 13/719756 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20280 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13719756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8791682 [patent_doc_number] => 20130108651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-02 [patent_title] => 'ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1' [patent_app_type] => utility [patent_app_number] => 13/719763 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20198 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13719763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9355543 [patent_doc_number] => 08674076 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-18 [patent_title] => 'BSL2vcvc-lg polypeptides' [patent_app_type] => utility [patent_app_number] => 13/711855 [patent_app_country] => US [patent_app_date] => 2012-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 62 [patent_no_of_words] => 76350 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13711855 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9216313 [patent_doc_number] => 08629113 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-14 [patent_title] => 'CTLA4-Ig immunoadhesins' [patent_app_type] => utility [patent_app_number] => 13/710305 [patent_app_country] => US [patent_app_date] => 2012-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 16 [patent_no_of_words] => 27661 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13710305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8744886 [patent_doc_number] => 20130084603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-04 [patent_title] => 'B7L-1 POLYNUCLEOTIDES' [patent_app_type] => utility [patent_app_number] => 13/693844 [patent_app_country] => US [patent_app_date] => 2012-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14276 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13693844 [rel_patent_id] =>[rel_patent_doc_number] =>)